Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2020; 10(Volume 10, Issue 4.000): 34-40


Growth inhibition of combined treatment of cationic liposome/p53 complexes and cisplatin on human carcinoma cells

Wanlop Weecharangsan,Robert J. Lee.




Abstract
Cited by 1 Articles

A combination of cationic liposome/green fluorescence protein (GFP)-p53 complexes and a chemotherapeutic drug, cisplatin was evaluated for therapeutic activity in human carcinoma cells. Cationic liposome/GFP-p53 complexes and cationic liposome/PEI 0.8K/GFP-p53 complexes were synthesized and evaluated in HeLa and in A549 cells for uptake and cytotoxicity, alone and in combination with cisplatin. The particle size of cationic liposome/GFP-p53 complexes and cationic liposome/PEI 0.8K/GFP-p53 complexes were 318±18 - 352±26 to 754±108 nm, and zeta potentials were -15.7±2.8 to +27±08 mV. The GFP expression upon the delivery by cationic liposome/pEGFP complexes and cationic liposome/PEI 0.8K/pEGFP complexes was demonstrated. Treatment of the cells with either cationic liposome/GFP-p53 complexes or cationic liposome/PEI 0.8K/GFP-p53 complexes inhibited cell growth. Upon post-treatment with cisplatin, the growth inhibition of the complexes was further increased in HeLa cells and significantly increased in A549 cells upon lipid-to-DNA ratio. This study concluded that the sensitivity to the cancer cells to cisplatin was dependent upon the cell line and the ratio of cationic liposome and GFP-p53. GFP-p53 expression delivered by cationic liposome/GFP-p53 complexes would be useful to increase the effect of cisplatin on the treatment of cancer cells.

Key words: cationic liposome, p53, polyethylenimine, growth inhibition, cisplatin, cancer






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.